The rebranding is part of changes, including new products, that the company says are forthcoming, according to QS/1 president Tammy Devine.
The New York Times outlines the impact price increases of Valeant Pharmaceutical's Cuprimine has on one family, juxtaposing Valeant's pharmaceutical business model against the threat of government action. “Cuprimine is just one of many Valeant drugs whose prices have spiked as part of the company’s concerted strategy, which has richly rewarded its investors and made it one of Wall Street’s most popular health stocks,” the article said. “But Valeant’s habit of buying up existing drugs and raising prices aggressively, rather than trying to develop new drugs, has also drawn the ire of lawmakers and helped stoke public outrage against the growing trend of higher and higher drug prices imposed by big drug companies.” (New York Times)
Overall, 22% of consumers who are enabling their health management through technology in 2015 vs. 13% two years ago.
Jason Ausili joined NACDS this week as the director of pharmacy affairs. Ausili will drive NACDS' initiatives designed to optimize pharmacy care and will assist with emerging care models.
Two Dutch pharmacy associations have presented a plan suggesting that widespread pharmacogenomics might be available by 2020.
The company will oversee the drug’s sale, marketing and distribution in the U.S. after acquiring the rights from Pragma Pharmaceuticals.
The pharmaceutical company is donating thousands of its Evzio auto-injectors ahead of a planned Oct. 4 Washington, D.C. rally for recognizing and treating opioid addiction.
Cohen had more than 30 years’ experience working in pharmacy- and specialty pharmacy-related organizations, and was known in the field as an advocate and visionary.
Bayer HealthCare Pharmaceuticals has appointed new president with more than 20 years of experience at the company.
Tussionex has launched its generic of Tussionex, taking over marketing and distribution from Par Pharmaceuticals after Par's rights to the drug expire.